Bajaj Healthcare Ltd · NSE:BAJAJHCARE
Bajaj Healthcare — Investor Presentation (June 2022)
35 slides from Bajaj Healthcare's investor presentation, Jun 27, 2022
Slide 1: Cover letter to BSE and NSE
Date: 27'4 June, 2022. BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5% Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex Bandra (East) Mumbai — 400 001 Mumbai-400051 Script Code : 539872 Script Code : BAFAJHCARE Dear Sir/Madam, Sub : Investors Presentation -
Slide 2: Bajaj Healthcare Limited Investor Presentation
Bajaj Healthcare Limited Your Trusted Associate in Pharmaceuticals & Healthcare Industry Investor Presentation June 2022
Slide 3: Safe Harbor
Safe Harbor Certain statements in this document may be forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause our actua
Slide 4: This is Bajaj Healthcare Ltd
This is Bajaj Healthcare Ltd PM’s Vision Indian pharmaceuticals industry to play a leading role in global market. Good quality pharmaceuticals of mass consumption to be made available in abundant at reasonable prices within the country. Bajaj’s contribution in line with PM’s vision. 02 BAJAJ HEALTHC
Slide 5: Corporate Overview
Corporate Overview Background Revenue Segment Commenced operation in the Year 1993, now headquartered B2B (FY 21-22) at Thane, Maharashtra. Engaged into manufacturing of Domestic v/s Export Sales Breakup of Revenue Active Pharmaceutical Ingredient (APIs), Intermediates, 1% Finished formulations & Nu
Slide 6: Corporate Overview
Corporate Overview Active Pharmaceutical Finished Dosage Intermediates Ingredients (APIs) Formulation (FDFs) We focus on efficiently manufacturing We focus manufacturing intermediates which We focus on manufacturing tablets, high-quality and high value APIs in key form a key input component for its
Slide 7: Vision & Mission
Vision & Mission VISION MISSION Our vision is to be a leading pharmaceutical Innovation and excellence with customer company in India and to become a significant satisfaction. global player by providing high quality and affordable products. Our mission at Bajaj Healthcare Limited is to become a glob
Slide 8: Key Milestones
Key Milestones Acquired Company listed on NSE. Commenced intermediate production at units Incorporated Manufacturing unit at plot no. N-92 and company and at MIDC, Tarapur T-30,MIDC, Tarapur Commenced establishment of an Maharashtra, from Maharashtra(acquired formulation Company listed APIs manufact
Slide 9: Leadership Pool
Leadership Pool Mr. Sajankumar R. Bajaj Mr. Anil C. Jain Ms. Namrata S. Bajaj Chairman & Managing Director Joint Managing Director Whole Time Director • Self- Driven, dedicated and hard- working leader • Pharma Industry expert, having excellent • Bachelors in business administration with over 30+ ye
Slide 10: Strong In-House R&D Center
Strong In-House R&D Center Our R&D centre is accredited by Department of Scientific & Industrial research, Ministry of Science and Technology, GOI Focus on developing a) Reverse Engineering of APIs b) Improving product quality c) Efficiency in pharma formulations Our team consists of PhD & Post Grad
Slide 11: Recent Additions to Our Production Capabilities
RECENT ADDITIONS TO OUR PRODUCTION CAPABILITIES Particulars Active Pharma Ingredients Intermediaries Formulations Existing Capacity 615 MT/p.m. 33 MT/p.m. 92 MN pcs/p.m. Additional Capacity: Manufacturing facility of - 61 MT/p.m. - Vetpharma Ltd. Additional Capacity: Manufacturing facilities 111 MT/
Slide 12: Aggregate Installed Capacity
Aggregate Installed Capacity 730 MT/p.m. 94 MT/p.m. 92 mn pcs/p.m. Active Pharma Intermediates Ingredients Formulations 10 BAJAJ HEALTHCARE LIMITED www.bajajhealth.com
Slide 13: Star Performers – Ascorbic Acid, Chlorhexidine Base & Citicholine Sodium
Star Performers – Ascorbic Acid, Chlorhexidine Base & Citicholine Sodium Ascorbic Acid Ascorbic Acid Derivatives Application Industry BHL is one of the leading Ascorbic acid coated (Stearyl Alcohol) Used in Food and Beverage industry manufacturers of Ascorbic Acid with Ascorbic acid coated (Ethyl Ce
Slide 14: Star Performers – Ascorbic Acid, Chlorhexidine Base & Citicholine Sodium
Star Performers – Ascorbic Acid, Chlorhexidine Base & Citicholine Sodium Trait of Chlorhexidine Base Citicoline Sodium Trait of Citicoline Sodium It is used as disinfectant and topical BHL one of the leading manufacturers of Citicoline Sodium is a nutritional anti-infective agent for mouthwash, to C
Slide 15: New APIs from Acquired Units
New APIs from Acquired Units Artemether Lumefantrine Arthemether is used to treat certain kinds of malaria infections Lumefantrine is an antimalarial agent used to treat acute (a serious infection that is spread by mosquitoes in certain uncomplicated malaria. It is administered in combination with p
Slide 16: APIs & Formulations Launched for COVID-19
APIs & Formulations Launched for COVID-19 “FAVIJAJ” (FAVIPIRAVIR) “IVEJAJ” (IVERMECTIN) “POSACONAZOLE API” “Favijaj” (Favipiravir) an antiviral drug “Ivejaj” (Ivermectin) an Anti-Parasitic “Posaconazole API” a triazole used for treating patients suffering Drug, which is used in controlling antifunga
Slide 17: Contd...
Contd... The use of High Dose of Intravenous Vitamin C for management of COVID-19 has shown promising results# BAJAJ HEALTHCARE LTD. India’s Largest Manufacturer of Vitamin C Now Introduces Ascorbic Acid Injections VITAJAJ-C R Affordable, Accessible & Safe Immune Booster Powerful Antioxidant Anti-in
Slide 18: BHL's Diversified Product Mix
BHL’s Diversified Product Mix Product Mix In Percentage Product Category Pandemic (2020-21) Post Pandemic (2021-22) Ascorbic Acid and its Derivatives 24.36% 17.51% CH Base and its Derivatives 24.67% 8.16% Others API Products & Formulations 50.97% 74.33% TOTAL 100.00% 100.00% • The product mix has be
Slide 19: New APIs Launched in FY21 & FY22
New APIs Launched in FY21 & FY22 Methyldopa Doxofylline Deferasirox This medication is used alone or with Doxofylline is used in the treatment Deferasirox is an iron chelator used to treat other medications to treat high blood and prevention of chronic obstructive chronic iron overload caused by blo
Slide 20: Certification and Quality
Certification and Quality APIs Savli Unit, APIs Tarapur Unit, Formulations Unit, Gujarat Maharastra Vadodara, Gujarat ISO 9001:2015 certified for Accredited with EU-GMP ISO 9001:2015 certified for the ISO 9001:2015 certified for its its management system for Certification from Croatia Manufacture an
Slide 21: Industry Dynamics
Industry Dynamics Global Pharma Market Indian Pharma Market The global pharmaceuticals market is expected to grow from $1454.66 India’s domestic pharmaceutical market is at US$ 42 billion in 2021 and billion in 2021 to $1587.05 billion in 2022 at a compound annual growth likely to reach US$ 65 billi
Slide 22: Clientele: Domestic and Global
Clientele: Domestic and Global API top Clients - Domestic Sun Pharma Ltd. Pfizer Ltd. Hindustan Unilever Abbott Healthcare P. Ltd. Glaxo Smith Kline plc API top Clients - Global Bajaj Medical LLC Lonza Group Interquim S.a. Nestle Group Evonik Industries AG Formulations top Clients - Domestic Koye Ph
Slide 23: Business Revenue Mix (% Terms)
Business Revenue Mix (% Terms) Particulars (D MN) FY2020 (%) FY2021 (%) FY2022 (%) Domestic Sales 3,173.36 77.40 4,394.59 66.90 5,113.91 75.22 Export Sales 926.72 22.60 2,175.25 33.10 1,684.99 24.78 Total 4,100.08 100.00 6,569.84 100.00 6,798.90 100.00 22.60% 33.10% 24.78% FY2020 FY2021 FY2022 77.40
Slide 24: Export… How have we grown?
Export… How have we grown? Export Sales (` MN) 797.45 748.07 926.72 2175.25 1684.99 FY18 FY19 FY20 FY21 FY22 No. of Countries 51 45 42 60+ 62+ FY18 FY19 FY20 FY21 FY22 22 BAJAJ HEALTHCARE LIMITED www.bajajhealth.com
Slide 25: Financial Highlights Q4FY22 vs Q4FY21
Financial Highlights Q4FY22 vs Q4FY21 Particulars (D MN) Q4 FY22 Q4 FY 21 Financial Comparison Q4FY22 vs Q4FY21 Revenue from Operations has grew by 33% Revenue from Operations 1,757.14 1,321.82 from Rs. 1321.82 Mn in Q4 FY21 to Rs. 1757.14 Other Income 4.48 21.52 Mn in Q4 FY22 mainly driven by incre
Slide 26: Profit/Loss Account
Profit/Loss Account Particulars (D MN) FY22 FY21 FY20 Revenue from Operations 6,798.90 6,569.84 4,100.08 Other Income 14.44 69.13 65.33 Total Revenue 6,813.34 6,638.96 4,165.41 Total Expenses including Depreciation, Amortization & 5,916.49 5,450.77 3,804.81 Finance Cost EBITDA 1,185.02 1,363.27 546.
Slide 27: Financial Profile FY21 vs FY22
Financial Profile FY21 vs FY22 Income from Operation has grown by 3.5% from Rs. 6569.84 MN in FY21 to Rs. 6798.90 MN in FY22 The EBITDA has degrown by 13.08% from Rs. 1363.27 Mn in FY21 to Rs. 1185.02 Mn in FY22 and there is a degrowth in the EBITDA margins from 20.75 % in FY21 to 17.43 % in FY22 Ne
Slide 28: Balance Sheet
Balance Sheet Particulars (D MN) FY22 FY21 FY20 Fixed Assets Tangible Assets 2,697.40 2,081.28 1,622.43 Intangible Assets - - - Capital Work in Progress 519.76 570.48 54.46 Total Fixed Assets 3,217.16 2,651.75 1,676.89 Non-current investment & other Financial Asset 0.03 0.03 50.03 Other Non-Current
Slide 29: Balance Sheet
Balance Sheet Particulars (D MN) FY22 FY21 FY20 Shareholders Fund Share Capital 137.99 137.99 137.99 Reserves and Surplus 3,146.86 2,446.11 1,641.33 Revaluation Reserves - - Total Shareholders Fund 3,284.85 2,584.11 1,779.32 Non- Current Liabilities Long Term Borrowing 663.10 797.13 235.78 Other Fin
Slide 30: Exhibiting values over the year
Exhibiting values over the year Revenue from Operations Sales Growth EBITDA EBITDA Margin (N in MN) (%) (N in MN) (%) 60.24 20.75 1,363.27 6,798.90 1,185.02 6,569.84 17.43 13.32 4,100.08 10.76 546.33 3.5 FY20 FY21 FY22 FY20 FY21 FY22 FY20 FY21 FY22 FY20 FY21 FY22 PAT PAT Margin Diluted EPS (N in MN)
Slide 31: Business Updates
Business Updates On July 11, 2021 a fire accident took place at plot commercial production at Plot no. N 92, no. 1717/1718, GIDC Panoli, Tal: Ankleshwar, MIDC, Tarapur, of ‘Nimesulide API’; used for District: Bharuch, Gujarat 394116 (one of the relief from pain and prevention of fever. This manufact
Slide 32: Strategy & Guidance
Strategy & Guidance Business Strategies Forward Guidance Focus to launch 3-4 new products, through reverse engineering in APIs During the next financial year, BHL will strive for operational excellence by FY2023 and moderate costs to drive profitability To focus on increasing global footprints for A
Slide 33: Shareholding Pattern
Shareholding Pattern Shareholding Pattern as on 31st March, 2022 Category of Shareholder Percentage of Shares Held (A) Promoter & Promoter Group 67.26% (B) Public 32.36% (C) FII 0.38% Grand TOtal 100% Market Indicators MARKET INDICATOR March 2022 Public 32.74% No of Equityshares 2,75,98,400 Face Val
Slide 34: CSR Initiative-Giving Back
CSR Initiative-Giving Back We believe that contributing back to the society is not only a Responsibility but a Commitment of our Company. Our little value addition to the betterment of society is a part of our mission, in line with our commitment to human health. Social Commitment is anchored in our
Slide 35: Thank you
Thank you Bajaj Healthcare Limited Your trusted associate in pharmaceuticals and healthcare industry Investor Relations Mr. Rupesh Nikam (CFO) Reg Office: 602 - 606, Bhomi Velocity Infotech Park, Captive IR Strategic Advisors (P) Ltd. Plot No. B-39, B-39 A B- 39 A/ 1, RD No. 23, Mr. Vinayak Shirodka